Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs nonâ€biologic systemic therapies
JEADV, 2021.
Mason KJ, Burden AD, Barker J, Lunt M, Ali H, Kleyn CE, McElhone K, Soliman MM, Green AC, Griffiths CEM, Reynolds NJ, Ormerod AD
Read publication: JEADV 2021
Related
Characteristics of "super responders" and "super nonresponders" to first biologic monotherapy for ps...
Atopic Polygenic Risk Score Is Associated with Paradoxical Eczema Developing in Patients with Psoria...
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective c...
0 Comments